Customized Adherence Enhancement for Individuals With Bipolar Disorder Receiving Antipsychotic Therapy
Supplemental Material
pss6302_0176_ds.pdf (12 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×Except for Dr. Tatsuoka, the authors are affiliated with the Department of Psychiatry, Case Western Reserve University, 10524 Euclid Ave., Cleveland, OH 44106 (e-mail: ).
Except for Dr. Tatsuoka, the authors are affiliated with the Department of Psychiatry, Case Western Reserve University, 10524 Euclid Ave., Cleveland, OH 44106 (e-mail: ).
Except for Dr. Tatsuoka, the authors are affiliated with the Department of Psychiatry, Case Western Reserve University, 10524 Euclid Ave., Cleveland, OH 44106 (e-mail: ).
Except for Dr. Tatsuoka, the authors are affiliated with the Department of Psychiatry, Case Western Reserve University, 10524 Euclid Ave., Cleveland, OH 44106 (e-mail: ).
Except for Dr. Tatsuoka, the authors are affiliated with the Department of Psychiatry, Case Western Reserve University, 10524 Euclid Ave., Cleveland, OH 44106 (e-mail: ).
Except for Dr. Tatsuoka, the authors are affiliated with the Department of Psychiatry, Case Western Reserve University, 10524 Euclid Ave., Cleveland, OH 44106 (e-mail: ).
pss6302_0176_ds.pdf (12 KB)
This study was supported by a grant from AstraZeneca (investigator-sponsored study IRUSQUET0455).
Dr. Sajatovic has received research grants from GlaxoSmithKline, AstraZeneca, Pfizer, and Merck and has served as a consultant to the Cognition Group, United BioSource Corp., ePharma Solutions, and Medco. The other authors report no competing interests.